CervoMed Inc. Files 8-K
Ticker: CRVO · Form: 8-K · Filed: Jul 12, 2024 · CIK: 1053691
| Field | Detail |
|---|---|
| Company | Cervomed Inc. (CRVO) |
| Form Type | 8-K |
| Filed Date | Jul 12, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, corporate-update
TL;DR
CervoMed filed an 8-K on 7/12, check it for updates.
AI Summary
CervoMed Inc. filed an 8-K on July 12, 2024, reporting other events and financial statements. The company, formerly known as Diffusion Pharmaceuticals Inc., RestorGenex Corp, and Stratus Media Group, Inc., is incorporated in Delaware and headquartered in Boston, MA.
Why It Matters
This filing provides an update on CervoMed Inc.'s corporate activities and financial reporting, which is important for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, not indicating any specific new risks or material changes.
Key Numbers
- 001-37942 — SEC File Number (Identifies the company's filing history with the SEC.)
- 30-0645032 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- CervoMed Inc. (company) — Registrant
- Diffusion Pharmaceuticals Inc. (company) — Former Company Name
- RestorGenex Corp (company) — Former Company Name
- Stratus Media Group, Inc (company) — Former Company Name
- 20 Park Plaza, Suite 424 Boston , Massachusetts 02116 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for CervoMed Inc.?
The 8-K filing reports on 'Other Events' and 'Financial Statements and Exhibits' for CervoMed Inc.
When was this 8-K filing submitted to the SEC?
The filing was submitted on July 12, 2024.
What are the previous names of CervoMed Inc. mentioned in the filing?
CervoMed Inc. was formerly known as Diffusion Pharmaceuticals Inc., RestorGenex Corp, and Stratus Media Group, Inc.
Where is CervoMed Inc.'s principal executive office located?
CervoMed Inc.'s principal executive office is located at 20 Park Plaza, Suite 424, Boston, Massachusetts 02116.
What is CervoMed Inc.'s fiscal year end?
CervoMed Inc.'s fiscal year ends on December 31st.
Filing Stats: 437 words · 2 min read · ~1 pages · Grade level 10.6 · Accepted 2024-07-12 16:05:15
Key Financial Figures
- $0.001 — on which registered Common Stock , $0.001 par value CRVO NASDAQ Capital Market
Filing Documents
- crvo20240711_8k.htm (8-K) — 28KB
- ex_697664.htm (EX-99.1) — 19KB
- 0001437749-24-022658.txt ( ) — 183KB
- crvo-20240711.xsd (EX-101.SCH) — 3KB
- crvo-20240711_def.xml (EX-101.DEF) — 11KB
- crvo-20240711_lab.xml (EX-101.LAB) — 15KB
- crvo-20240711_pre.xml (EX-101.PRE) — 11KB
- crvo20240711_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events On July 11, 2024, CervoMed Inc. (the "Company") issued a press release announcing its intention to host a virtual key opinion leader event related to neflamapimod for the treatment of patients with dementia with Lewy bodies on July 23, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release, issued July 11, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 12, 2024 CervoMed Inc. By: /s/ William Elder Name: William Elder Title: Chief Financial Officer & General Counsel